IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Company ParticipantsPatrick Mercer - President and CEOPhilip Taylor - Principal and Investor Relations Contact of IRIDEXRomeo Dizon - CFOConference Call ParticipantsScott Henry - Managing Director and Senior Research AnalystOperatorThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX earnings conference call. All lines have been placed ...

IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Company ParticipantsPatrick Mercer - President and CEOPhilip Taylor - Principal and Investor Relations Contact of IRIDEXRomeo Dizon - CFOConference Call ParticipantsScott Henry - Managing Director and Senior Research AnalystOperatorThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX Earnings Conference call. All lines have been placed ...

IRIDEX (NasdaqCM:IRIX) Q4 2025 Earnings call March 26, 2026 05:00 PM ET Speaker0Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 IRIDEX Earnings Conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you'd like to ask a question during this time, simply press star followed by 1 on your telephone keypad. I ...

Core Insights - Edwards Lifesciences (EW) has achieved a remarkable 22.1% return over the past year, significantly outperforming the industry's decline of 3.8% and closely aligning with the S&P 500's rise of 23.5% [1][8] Company Performance - The company is currently ranked 2 (Buy) by Zacks and has shown consistent growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, while effectively scaling its fast-growing businesses [2] - The Transcatheter Aortic Valve Replacement (TAVR) platform has benefited from technological advancements like RESILIA and increased global adoption, with TAVR sales exceeding $1 billion for the fifth consecutive quarter [2][6] - The Surgical Structural Heart business is experiencing robust uptake of premium surgical technologies globally, contributing to overall growth [2][10] Recent Developments - On September 3, 2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion, enhancing its balance sheet flexibility for investments in new technologies [3] - The company has seen strong momentum in the TMTT segment, driven by the global adoption of PASCAL and EVOQUE systems, which provide solutions for mitral and tricuspid patients [4][8] - The EVOQUE system became eligible for all Medicare beneficiaries with symptomatic tricuspid regurgitation in March 2025, and the SAPIEN M3 mitral valve replacement system received CE Mark approval in April 2025 [5] Financial Estimates - The Zacks Consensus Estimate projects a 14.8% increase in earnings per share (EPS) for 2026 to $2.94 and a 12.2% increase for 2027 to $3.30, with revenues expected to grow 9.6% to $6.65 billion in 2026 and 9.8% to $7.30 billion in 2027 [12]

Summary of Edwards Lifesciences Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Technology, specifically focusing on heart valve therapies and surgical solutions Key Points and Arguments TAVR (Transcatheter Aortic Valve Replacement) - **Clinical Data Impact**: The presentation of EARLY TAVR clinical trial data in late 2024 significantly boosted confidence in the durability of the SAPIEN valve family, leading to increased business momentum in 2025 [3][4] - **Growth Drivers**: The second half of 2025 saw a 10.6% growth in U.S. TAVR, attributed to increased urgency in treating severe aortic stenosis, driven by new clinical data [9][10] - **2026 Growth Guidance**: Projected TAVR growth of 6%-8% for 2026, with confidence in this guidance due to a global footprint of approximately 2,000 sites performing SAPIEN procedures [11][12] - **NCD and Guidelines**: Upcoming National Coverage Determination (NCD) and updates to U.S. guidelines are critical for future TAVR performance [14][15] TMTT (Transcatheter Mitral and Tricuspid Therapies) - **Portfolio Expansion**: For the first time, Edwards offers both repair and replacement solutions for mitral and tricuspid regurgitation, enhancing its position as a partner for physicians [5][24] - **Market Dynamics**: The TMTT market is growing, with PASCAL being the current revenue leader, while EVOQUE is growing at a faster rate [26][27] - **Clinical Trials**: Upcoming clinical trial data, such as CLASP II TR and TRISCEND II, are expected to provide insights into the performance of PASCAL and EVOQUE [29][30] Surgical Innovations - **New Solutions**: Edwards is preparing to introduce a left atrial appendage (LAA) closure solution, complementing its existing surgical portfolio [47][48] - **Investment in Surgical**: Continued investment in surgical innovations reflects the company's commitment to expanding its offerings in valvular disease treatment [48] Financial Performance - **Gross Margin Guidance**: Expected gross profit margin of 78%-79% for 2026, with operating profit margin projected to grow by 150 basis points [51] - **R&D Investments**: R&D as a percentage of sales is expected to decrease from 19.4% in 2024 to around 17% in 2026, indicating a focus on efficiency while driving innovation [53][54] Capital Allocation and M&A Strategy - **External Investments**: Edwards is open to external investments, focusing on early-stage technologies that complement internal innovations in structural heart [55][56] Innovation Focus - **Core Strategy**: The company emphasizes the importance of innovation as the foundation of its culture and business strategy, aiming to maintain leadership in the structural heart market [57] Additional Important Insights - **Physician Engagement**: The company is focused on improving treatment rates for patients with mitral and tricuspid regurgitation, rather than merely capturing market share [26] - **Patient Outcomes**: Positive anecdotal evidence from patients treated with EVOQUE highlights the significant impact of the therapy on quality of life [32] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, providing a comprehensive overview of the company's current position and future outlook in the medical technology industry.

Edwards Lifesciences FY Conference Summary Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Scott Ullem (CFO), Mark Wilterding (Head of Investor Relations), Sydney Bailey (Investor Relations Team) Core Industry Insights - **Sustainable Growth**: Edwards Lifesciences aims for double-digit sustainable growth, driven by established TAVR business and emerging TMTT (Transcatheter Mitral and Tricuspid Therapies) [3][4] - **TAVR Business**: TAVR remains a cornerstone of growth, expected to grow mid-single digits annually [7] - **TMTT Growth**: TMTT is projected to reach $2 billion in revenue by 2030, with expected growth rates of 35%-45% in 2026 [7][8] Financial Projections - **TMTT Revenue**: Expected to grow from over $500 million in 2025 to $740 million-$780 million in 2026 [8] - **Overall Growth Expectation**: Anticipated double-digit growth of approximately 10% annually, combining TAVR, TMTT, and surgical business performance [8] Product Development and Market Strategy - **Innovative Therapies**: Introduction of new therapies like PASCAL for mitral and tricuspid, and SAPIEN M3 for mitral valve replacement, providing options for patients historically limited to surgical interventions [10][11] - **Heart Failure Management**: Development of Cordella device for heart failure management, addressing a significant patient population with limited treatment options [16][17] - **Aortic Regurgitation**: Acquisition of technology for catheter-based replacement of diseased aortic valves, with a focus on addressing different disease states [21][22] Market Opportunities - **EARLY TAVR Trial**: Results from the trial indicate the need for valve replacement in severe aortic stenosis patients regardless of symptoms, leading to increased physician interest [25][26] - **CMS Evaluation**: Anticipation of a more accommodating National Coverage Determination (NCD) to facilitate patient referrals for valve replacement [26] Long-term Vision - **Comprehensive Care**: Emphasis on developing multi-device and multi-therapy solutions for patients at risk of heart failure, recognizing the interplay between different structural heart conditions [20][21] - **Strategic Investments**: Commitment to investing in technologies that align with core competencies, particularly in structural heart failure [21] Additional Considerations - **Patient Eligibility**: Importance of a toolkit approach to cater to diverse patient anatomies and treatment needs, ensuring tailored therapeutic interventions [13] - **Market Dynamics**: Recognition of differing opinions within the medical community regarding the timing of treatment for aortic stenosis patients [28]

Summary of Edwards Lifesciences FY Conference Call (March 10, 2026) Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Devices, specifically focusing on heart valve therapies and structural heart disease solutions Key Points and Arguments Growth Strategy - **Sustainable Growth**: The company aims for double-digit sustainable growth through investments in differentiated technologies and platforms that address large patient populations [5][6] - **TAVR Business**: Transcatheter Aortic Valve Replacement (TAVR) remains a cornerstone of growth, driving innovation and revenue [5][6] - **Emerging Businesses**: The Transcatheter Mitral and Tricuspid Therapies (TMTT) are expected to grow significantly, with a long-term revenue target of $2 billion by 2030 [8][9] Financial Projections - **TMTT Growth**: Expected to grow from over $500 million in 2025 to $740 million-$780 million in 2026, with a growth rate of 35%-45% [9] - **TAVR Growth**: Projected to grow mid-single digits annually, indicating a shift as TMTT becomes a larger contributor to overall growth [8][9] Product Development - **Innovative Therapies**: Introduction of new therapies such as SAPIEN M3 for mitral valve replacement and EVOQUE for tricuspid replacement, providing options for patients historically limited to surgical interventions [11][12] - **Heart Failure Management**: Development of the Cordella device for heart failure management, indicating a strategic move into this area due to the lack of treatment options [17][18] Market Dynamics - **Early TAVR Trial**: Results from the Early TAVR trial have shifted physician perspectives on treating aortic stenosis, emphasizing the need for valve replacement regardless of symptoms [25][37] - **Regulatory Environment**: Anticipation of changes in national coverage determinations (NCD) to facilitate easier access for patients needing valve replacements [26] Operational Considerations - **Margin Expansion**: The company expects about 150 basis points of operating margin expansion this year, with a long-term goal of 50-100 basis points annually [40] - **Investment in Growth**: Emphasis on balancing investments in R&D and market development with achieving margin expansion [40][42] Risk Factors - **Market Competition**: The company faces competition in the TMTT space, particularly as it seeks to capture market share from established players [10][11] - **Geopolitical Concerns**: Current focus on employee safety in the Middle East amid regional tensions, with uncertain long-term impacts on operations [45] Additional Important Insights - **Comprehensive Care Approach**: The company is exploring multi-device and multi-therapy solutions for patients at risk of heart failure, indicating a long-term strategy to address complex patient needs [20][21] - **Technological Investments**: Ongoing investments in technologies like Vectorious for heart failure management, showcasing a commitment to expanding treatment options for underserved patient populations [18][22] This summary encapsulates the key discussions and insights from the Edwards Lifesciences FY Conference Call, highlighting the company's strategic direction, financial outlook, and operational challenges.

Summary of Edwards Lifesciences FY Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Devices, specifically focusing on heart valve therapies Key Points Executive Transition and Succession Planning - The company is undergoing an external search for a new CFO, with a focus on ensuring a smooth transition and maintaining a strong executive team [6][7] - The leadership transition is seen positively, with a deep bench of talent within the organization [8] TAVR Franchise and Market Position - Edwards maintains a dominant share in the U.S. TAVR (Transcatheter Aortic Valve Replacement) market, with a renewed focus on the treatment of aortic stenosis [9][11] - Recent clinical data, including 7-year durability data for the SAPIEN platform, has reinforced the efficacy and safety of TAVR, leading to increased market growth and adoption [12][18] - The company expects TAVR full-year growth rates of 6%-8% for 2026, with a focus on increasing patient access rather than just market share [18][43] Asymptomatic Patient Adoption - The approval for asymptomatic patients has been a significant development, with guidelines evolving to promote earlier treatment [22][23] - The EARLY TAVR trial demonstrated that symptoms are not a prerequisite for treatment, which is expected to increase patient referrals and treatment rates [21][24] - The company is optimistic about the potential for asymptomatic patients to contribute to overall market growth once national coverage decisions (NCD) are finalized [34][36] Product Development and Innovation - The SAPIEN 3 Ultra RESILIA valve is highlighted as a key innovation, with ongoing global rollout and positive clinical trial results [16][32] - Edwards is committed to continuous innovation, with next-generation products like SAPIEN X4 in development [16][50] - The company is also focused on expanding its transcatheter mitral and tricuspid therapies (TMDT), aiming for $2 billion in sales by 2030 [44][50] Financial Performance and Profitability - The company anticipates operating margin expansion of 50-100 basis points annually, driven by lower growth rates in expenses compared to sales [40][41] - TMDT generated $545 million in sales in 2025, with expectations of $740 million to $780 million in 2026 [39][40] - The focus remains on maintaining profitability while investing in growth across various platforms [39][43] Market Competition and Strategy - Edwards is positioned as a leader in structural heart care, with a focus on providing a range of treatment options for mitral and tricuspid regurgitation [50] - The company acknowledges the presence of competition but emphasizes its commitment to addressing patient needs rather than competing with other companies [51] Recent Developments and External Factors - The company is monitoring geopolitical events, particularly in the Middle East, to ensure the safety of employees and the availability of therapies in the region [56][57] Additional Insights - The transition from a watchful waiting approach to proactive treatment for severe aortic stenosis is a critical shift in clinical practice [22][29] - The success of the EVOQUE product for tricuspid regurgitation is promising, with positive early results and significant patient outcomes [53][54] This summary encapsulates the key discussions and insights from the Edwards Lifesciences FY Conference Call, highlighting the company's strategic direction, market positioning, and future growth opportunities.

Summary of Edwards Lifesciences Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Technology, specifically focusing on heart valve therapies and critical care technologies Key Points TAVR Market Dynamics - The TAVR (Transcatheter Aortic Valve Replacement) market experienced an acceleration in growth, reaching **11% revenue growth** in the latest quarter, compared to a market growth of **7% to 8%** [5][6] - Factors contributing to this growth include the introduction of new therapies like **EVOQUE** and positive clinical trial results from the **EARLY TAVR Trial** [6][7] - Hospitals are returning to a status quo, adjusting their capacities to accommodate new therapies, which had previously lagged [6] Clinical Trials and Regulatory Changes - The upcoming **NCD (National Coverage Determination)** guidelines in the U.S. are expected to evolve, similar to changes seen in Europe in 2025, which may further influence TAVR adoption [8][12] - Feedback on the NCD process has been limited, with a draft expected in **June or July** [12] - The company is optimistic about the potential benefits of TAVR for patients with moderate aortic stenosis, with trial results anticipated in **December** [35][36] Market Share and Pricing - Edwards gained market share in Europe due to a competitor exiting the region, reallocating their position across competitors [20] - Pricing for TAVR has remained stable globally, with expectations of average selling price compression as hospitals increase volumes [21][23] TMTT (Transcatheter Mitral and Tricuspid Therapies) - The TMTT segment is growing, with a focus on both mitral and tricuspid therapies, although mitral TEER (Transcatheter Edge-to-Edge Repair) currently represents a larger share of the business [44][51] - The company is awaiting data on tricuspid TEER and has enrolled trials for functional mitral regurgitation (FMR) [49][50] Innovations and Acquisitions - Recent acquisitions include **JC Medical**, focusing on aortic regurgitation, and **Cordella**, a heart failure management technology [101][102] - The company emphasizes the importance of innovation in sustaining growth in surgical and transcatheter therapies [86][87] Financial Outlook - Edwards maintains a sales growth guidance of **8%-10%** for the company and **6%-8%** for TAVR, reflecting increased confidence in their growth trajectory [116][120] - The company plans to continue share repurchases, having bought back nearly **$900 million** in stock last year [111][113] Broader Market Context - The MedTech sector has faced challenges, but Edwards remains optimistic about its growth potential and the number of untreated patients [122][124] - The company aims to increase awareness of mitral and tricuspid diseases, which are currently under-treated compared to aortic stenosis [65][71] Future Expectations - In the next year, discussions will likely focus on the outcomes of the NCD, the evolution of U.S. guidelines, and the penetration of new products like **PASCAL**, **EVOQUE**, and **SAPIEN M3** into the market [126][128] Additional Insights - The company is focused on educating both patients and physicians about heart diseases and treatment options, which is crucial for increasing treatment rates [77][82] - The role of robotic surgery in cardiac procedures remains uncertain, but the company welcomes advancements in this area [92][93]

Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]